Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Conferences
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • ESMO19
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM
    • Mol Targets
    • SABCS
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
  • Targets
    • Bispecifics
    • Cytokines
    • MYC
    • Neoantigens
    • STING
  • About
  • Contact
  • Pricing
  • Premium Content
  • Immuno-Oncology
  • Cell Therapy
  • Interviews
  • Podcast
  • Login

  • Through the window on the MYC oncogene

    Read more

  • Novel DDR combinations and regimens that could make a difference

    Read more

  • A STING in the long tail?

    Read more
  • Lightning bolt

    Is the BMS CheckMate-227 trial a hit or miss in lung cancer?

    Read more

  • Insights on the Jounce-Celgene collaboration and ICOS agonism

    Read more

  • New developments in Sarcoma

    Read more
E

Through the window on the MYC oncogene

What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?

View post
E

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

View post
E

A STING in the long tail?

What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?

View post

Terms of Use & Privacy Policy
Copyright © 2010-19 Biotech Strategy Blog

Sign Up for New Post Alerts
error: Content is protected !!